A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...

The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin condition affecting about 75,000 ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...

Please provide your email address to receive an email when new articles are posted on . Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life ...

Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and ...

San Diego — Nemolizumab, the first-in-class inhibitor of interleukin-31 (IL-31), a neuroimmune cytokine linked to the promotion of pruritis and inflammation, continues to show good efficacy and safety ...

Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Please provide your email address to receive an email when new articles are posted on . By week 100, 90% of participants achieved a 4-point or higher improvement in itch and 70% experienced an ...